Patients can experience “brain fog” even months after recovering from covid-19

El mundo tiene grandes desafíos en materia de salud mental.

The world has great mental health challenges.

Photo: OLIVIER DOULIERY / AFP / Getty Images

A new study indicates that the cognitive decline called “brain fog” reported by COVID-19 patients – even some who did not require hospitalization – can remain in them for months after their recovery.

“In this study, we found a relatively high frequency of cognitive decline several months after patients became ill with COVID-19.

“Impairments in executive functioning, processing speed, category fluency, memory encoding, and recall were predominant among hospitalized patients,” said Jacqueline Becker and other experts from the Icahn Mount Sinai School of Medicine. , In New York.

The research, which was published by the JAMA Network Open magazine, found that about a quarter of the disease patients in a Mount Sinai Health System registry had memory problems.

While hospitalized patients were more prone to “brain fog,” other outpatients suffered the same cognitive decline.

“This pattern – continues the report – is consistent with the first reports that describe a dysexecutive syndrome after COVID-19 and has considerable implications for occupational, psychological and functional outcomes.”

It is worth mentioning that other research found that up to one in three people with COVID-19 had neurological symptoms or mental health problems over a longer term, around half a year. This is the one published in the Lancet Psychiatry magazine last April.

For the CDC, this difficulty concentrating or thinking is among the list of conditions after COVID-19.

He adds that “although most people with COVID-19 improve within a few weeks of illness, some experience subsequent conditions. These conditions are a wide range of new, recurring or continuous health problems that people can experience four weeks or more after being infected for the first time with the virus that causes covid-19 ”.

The researchers conclude that “further studies are needed to identify the risk factors and mechanisms underlying cognitive dysfunction, as well as rehabilitation options.”

This also interests you:
– FDA indicates that Pfizer’s vaccine appears to be very effective for young children
– What happens if I combine COVID-19 vaccines in the booster dose?
– What are the vaccines approved by the United States to enter as of November 8?


See also  Monkeypox: First Confirmed Pediatric Case in Florida

Leave a Comment

Your email address will not be published.